论文部分内容阅读
质子泵抑制剂(PPI)径近十年临床实践已成为治疗酸相关性疾病的主流药物。继奥美拉唑及兰索拉唑之后,第三个质子泵抑制剂—泮托拉唑也已问世,并在我国上市—泰美尼克(TM)。其疗效及安全性更趋完善,与同类药物相比,有如下三大优点。1.高选择性、高稳定性 泮托拉唑与奥美拉唑及兰索拉唑一样均作用于胃壁细胞的H~+—K~+ATP酶。但与奥美拉唑及兰索拉唑
Proton pump inhibitor (PPI) diameter of nearly 10 years of clinical practice has become the mainstream drug for the treatment of acid-related diseases. Following omeprazole and lansoprazole, the third potent proton pump inhibitor, pantoprazole, has also been released and marketed in China - Tammic (TM). Its efficacy and safety are more perfect, compared with similar drugs, has the following three major advantages. 1. High selectivity, high stability Pantoprazole and omeprazole and lansoprazole are the same role in the gastric parietal cells H ~ + -K ~ + ATPase. But with omeprazole and lansoprazole